Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCMKTS:NSPDF) has revealed that it is submitting further information to Health Canada as part of its fast-track application for a Phase 2 trial of Cavaltinib to treat coronavirus (COVID-19).
The group also said it has now submitted the clinical trial design protocol through the proposed joint venture with Biologic Pharmamedical Research. Cavaltinib is licensed to a joint venture owned by Naturally Splendid and Biologic Pharmamedical Research based on technology and patents developed by Biologic.
READ: Naturally Splendid updates investors on Health Canada application for Phase 2 Cavaltinib trial for coronavirus
The candidate has been shown to inhibit IL-6 and several other cytokines central to the 'cytokine storm' phenomenon, where the body starts to attack its own cells rather than just fighting off the virus, seen in critically ill COVID-19 patients.
Naturally Splendid noted that data from the research of this patented technology associated with Cavaltinib was consistent with treatment protocols that medical experts believe will offer effective treatment for coronavirus patients.
"This has been an eighteen-year journey for me," said Franco Cavaleri, the researcher from Biologic Pharmamedical responsible for these discoveries in a statement.
"The discoveries made with this technology were made long before our COVID-19 crisis. While we have put this pharmacology to good use in the human population to treat other ailments, this novel variant of the drug may serve an even bigger impact on human health and wellness in the battle against COVID-19."
Cavaltinib may also serve as a prophylactic measure in the future as we face other similar threats, Naturally Splendid said.
"The world has evolved to a population density and reach that presents the conditions for virus species jumping and efficient transmission of infection. While research treatment options for today's crisis remain the shorter-term need, it must be kept in mind how this proposed treatment model can serve us in the future," the health food-focused firm added.
Shares in Toronto advanced 10% to C$0,055.
Contact the author at [email protected]